Search Results
- < Prev
1 of 1
- Next >
News Releases
-
May 10, 2013, 08:00 ET
Arena Pharmaceuticals to Present at the Bank of America Merrill Lynch 2013 Health Care Conference
Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the company is scheduled to present a corporate overview at the Bank of America Merrill Lynch 2013 Health Care Conference on Wednesday, May 15, 2013, at 2:20 p.m. Pacific Time (5:20 p.m. Eastern Time), at the Encore at the Wynn Las...
More news about: Arena Pharmaceuticals, Inc.
-
May 07, 2013, 15:30 ET
Arena Pharmaceuticals Provides Update on Upcoming US Launch of BELVIQ® (lorcaserin HCl) for Chronic Weight Management
Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the Office of the Federal Register filed for public inspection the US Drug Enforcement Administration's (DEA) final rule placing BELVIQ (pronounced BEL-VEEK) into Schedule IV of the Controlled Substances Act. The scheduling...
More news about: Arena Pharmaceuticals, Inc. , Eisai Inc.
-
May 02, 2013, 16:03 ET
Arena Pharmaceuticals Provides Corporate Update and Reports First Quarter 2013 Financial Results
Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today provided a corporate update and reported financial results for the first quarter ended March 31, 2013. Recent Developments: BELVIQ® (lorcaserin HCl) - The American Association of Clinical Endocrinologists (AACE) published its...
More news about: Arena Pharmaceuticals, Inc.
-
Apr 26, 2013, 08:00 ET
Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Thursday, May 2
Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that it will provide a corporate update and discuss first quarter 2013 financial results after the NASDAQ Global Select Market closes on Thursday, May 2, 2013. The conference call and webcast will begin at 5:15 p.m. Eastern Time (2:15 p.m....
More news about: Arena Pharmaceuticals, Inc.
-
Apr 05, 2013, 08:00 ET
Arena Pharmaceuticals Initiates Phase 1 Clinical Trial of APD334 for Autoimmune Diseases
Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today the initiation of dosing in a Phase 1 clinical trial of APD334, a novel oral drug candidate that targets the sphingosine 1-phosphate subtype 1 (S1P1) receptor for the potential treatment of autoimmune diseases. This randomized,...
More news about: Arena Pharmaceuticals, Inc.
-
Apr 01, 2013, 08:00 ET
Arena Pharmaceuticals Announces Eisai's Submission of BELVIQ® (lorcaserin HCl) Marketing Authorization Application in Mexico
Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that Eisai Laboratorios S. de R.L. de C.V., a subsidiary of Eisai Inc., has submitted a marketing authorization application (MAA) for BELVIQ® (lorcaserin HCl) in Mexico with the Federal Commission for the Protection Against Sanitary...
More news about: Arena Pharmaceuticals, Inc. , Eisai Laboratorios S. de R.L. de C.V. , Eisai Inc. , Ildong Pharmaceutical Co., Ltd.
- < Prev
1 of 1
- Next >
Modify your Search
 |
Quickly search for PR Newswire releases by adding our plugin to your browser search |